Figure 5.

Effects of prior treatment with eribulin on antitumor activity of capecitabine in the MDA-MB-231 human breast cancer xenograft model in nude mice. When the mean MDA-MB-231 xenograft tumor volumes reached approximately 200 mg (day 1), nude mice were randomly divided into control (non-treatment), capecitabine (540 mg/kg, QD8, p.o.) and eribulin (1.0 mg/kg,QD1, i.v.) groups. Following treatment in the eribulin group, when tumor volumes had recovered to the initial target level of tumor size (i.e. approximately 200 mg; on day 12, see Fig. S3), eribulin-treated mice were then randomly divided into new control (eribulin-pretreated) and capecitabine (eribulin-pretreated) groups as if on a new day 1. Each group consisted of 6 mice. Data are means ± SEM. *P < 0.05 versus after eribulin treatment by Student's t-test. NS, not significant.